Near-Patient Molecular Solutions Market Report 2026

The near-patient molecular solutions market size has grown strongly in recent years. It will grow from $4.54 billion in 2025 to $4.99 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to expansion of molecular diagnostic techniques, demand for rapid test turnaround times, decentralization of laboratory services, growth in outpatient diagnostic settings, adoption of portable diagnostic instruments.

The near-patient molecular solutions market size is expected to see strong growth in the next few years. It will grow to $7.17 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing focus on personalized medicine, rising demand for home and remote testing solutions, technological advancements in miniaturized molecular platforms, expansion of infectious disease surveillance, integration with digital health ecosystems. Major trends in the forecast period include increasing adoption of point-of-care molecular testing devices, rising demand for rapid infectious disease diagnostics, growing integration of portable PCR platforms, expansion of decentralized diagnostic infrastructure, enhanced focus on near-patient testing accuracy.

Growing demand for home-based point-of-care devices is expected to propel the growth of the near-patient molecular solutions market in the coming years. Home-based point-of-care devices are diagnostic systems that patients or non-laboratory users can operate at or near their home, allowing sample collection, analysis, or result interpretation outside conventional central laboratory settings. This demand is rising due to increasing consumer preference for convenient, rapid, and accessible health monitoring beyond traditional healthcare environments. Near-patient molecular solutions support these devices by providing accurate, portable, and rapid molecular diagnostics that can be reliably used outside standard laboratory settings. For instance, in February 2023, the US Food & Drug Administration (FDA) reported that in its 2023 COVID-19 testing update, there was one Emergency Use Authorization (EUA) for a molecular prescription at-home test, two EUAs for antigen prescription at-home tests, 26 EUAs for antigen over-the-counter (OTC) at-home tests, and four EUAs for molecular OTC at-home tests. Therefore, the rising demand for home-based point-of-care devices is driving the near-patient molecular solutions market.

Companies in the near-patient molecular solutions market are focusing on technological innovations, such as isothermal nucleic acid amplification, to enhance testing efficiency, portability, and diagnostic accuracy. Isothermal nucleic acid amplification is a molecular diagnostic method that amplifies target nucleic acid sequences at a constant temperature, removing the need for thermal cycling as in conventional polymerase chain reaction (PCR). This enables rapid, sensitive, and compact molecular testing. For example, in June 2023, Cue Health Inc., a US-based healthcare technology company, received FDA marketing authorization for the Cue COVID-19 Molecular Test, an isothermal amplification-based diagnostic device for at-home and point-of-care detection of SARS-CoV-2 RNA. The system uses a single-use cartridge, a Bluetooth-enabled reader, and a mobile app to guide users and deliver results in about 20 minutes. This test improves access to molecular-level diagnostics, reduces turnaround time, and supports real-time health decisions outside traditional laboratory environments.

In July 2024, Roche Holding AG, a Switzerland-based provider of in-vitro diagnostics and pharmaceutical solutions, acquired LumiraDx’s point-of-care technology business for $353.5 million. Through this acquisition, Roche gained access to LumiraDx’s portable, multi-assay diagnostic platform, enhancing its decentralized and near-patient testing capabilities, expanding its presence in primary care and community-based settings, and improving rapid, reliable diagnostics outside conventional laboratories. LumiraDx Group Limited, a UK-based company, is known for its compact instrument integrating immunoassay, clinical chemistry, and emerging molecular testing for near-patient applications.

Major companies operating in the near-patient molecular solutions market are Bosch Healthcare Solutions GmbH, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Hologic Inc., bioMérieux SA, Sysmex Corporation, QuidelOrtho Corporation, QIAGEN NV, DiaSorin SpA, OraSure Technologies Inc., Molbio Diagnostics Pvt Ltd, Cue Health Inc., Biocartis Group NV, Vela Diagnostics Pte Ltd, Co-Diagnostics Inc., Hyris Ltd, Genedrive plc.

North America was the largest region in the near-patient molecular solutions market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the near-patient molecular solutions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the near-patient molecular solutions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the near-patient molecular solutions market by increasing costs of imported diagnostic instruments, reagents, microchips, and optical components used in portable testing systems. Healthcare providers in North America and Europe are most affected due to reliance on imported molecular platforms, while Asia-Pacific faces higher manufacturing and export costs. These tariffs are raising device prices and slowing adoption in cost-sensitive settings. However, they are also driving local manufacturing of diagnostic devices, regional reagent production, and innovation in affordable point-of-care molecular solutions.

The near-patient molecular solutions market research report is one of a series of new reports that provides near-patient molecular solutions market statistics, including near-patient molecular solutions industry global market size, regional shares, competitors with a near-patient molecular solutions market share, detailed near-patient molecular solutions market segments, market trends and opportunities, and any further data you may need to thrive in the near-patient molecular solutions industry. This near-patient molecular solutions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Near-patient molecular solutions are diagnostic tests that employ molecular biology techniques, such as DNA or RNA detection, and are conducted at or near the point of patient care. These tests analyze small biological samples on-site rather than sending them to central laboratories, enabling rapid and accurate detection of pathogens or biomarkers using portable or simplified instruments. By providing fast and reliable results in outpatient, emergency, or remote settings, they support timely treatment decisions and improved health outcomes.

The main product types of near-patient molecular solutions include infectious disease testing kits, urinalysis kits, tumor or cancer marker tests, pregnancy and fertility tests, hematology testing kits, glucose monitoring kits, drugs-of-abuse testing kits, coagulation monitoring kits, cardiometabolic monitoring kits, and others. Infectious disease testing kits are designed to quickly detect and identify pathogens, including bacteria, viruses, or parasites, in patient samples to facilitate prompt diagnosis and treatment. Technologies used include PCR-based, genetic sequencing-based, and hybridization-based methods. End-users include hospitals and clinics, ambulatory care centers, research laboratories, home care settings, and others.

The near-patient molecular solutions market consists of sales of sample preparation devices, nucleic acid extraction kits, portable molecular analyzers, isothermal amplification kits, microfluidic cartridges, and multiplex detection panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.